Cue Biopharma (CUE) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cue Biopharma (CUE) has outperformed Spruce Biosciences (SPRB) over the past year, losing 30.0% versus a loss of 74.9%. Over five years, CUE leads with a -95.3% price change compared with -99.8% for SPRB. Cue Biopharma is the larger company by market cap ($121.4 million vs $114.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | SPRB |
|---|---|---|
| Share price | $16.71 | $39.65 |
| Market cap | $121.39M | $113.95M |
| 1-day change | -10.50% | -4.39% |
| YTD return | +82.62% | -54.48% |
| 1-year return | -30.03% | -74.88% |
| 5-year return | -95.32% | -99.84% |
| Forward P/E | — | 7.97 |
| EPS (TTM) | $-29.59 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | $0 |
| Revenue growth (YoY) | +195.75% | -100.00% |
| Net income (latest FY) | $-26.60M | $-38.97M |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $154.95 |
| 52-week low | $4.98 | $38.06 |
| Distance from 52-week high | -63.27% | -74.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +426.63% | +273.27% |
| Average volume | 272.41K | 78.11K |
| Shares outstanding | 7.26M | 2.87M |
| Employees | 29 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed SPRB by 44.9 percentage points over the past year.
- Cue Biopharma grew revenue faster in its latest fiscal year (+195.75% vs -100.00%).
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CUE vs SPRB FAQ
Which is bigger, Cue Biopharma or Spruce Biosciences?
Cue Biopharma (CUE) is larger, with a market capitalization of $121.39M compared with $113.95M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, CUE or SPRB?
CUE returned -30.03% over the past 12 months, compared with -74.88% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.